Medical News

RSS

Hospitalizations and associated costs with peripheral artery disease increase as condition progresses

Peripheral artery disease (PAD) is a progressive and costly disease, but remains under-diagnosed and under treated. While current PAD treatments are effective at clearing artery blockages in the lower leg, high recurrence rates and the subsequent need for repeat procedures are costly. Even after initial procedures to clear blockages in leg arteries, hospitalizations and associated costs in patients with peripheral artery disease increase as the condition progresses, according to research reported in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.

13 Oct 2010

$1.5 million DOD award allows U-M scientists to pursue new application for nanoemulsion technology

The U.S. Department of Defense has awarded $1.5 million over three years to the Michigan Nanotechnology Institute for Medicine and Biological Sciences and to Ann Arbor-based NanoBio Corporation to develop and test nanoemulsions with potential to fight a wide range of wound infections, including drug-resistant forms.

13 Oct 2010

Pharmalink's Nefecon for IgA nephropathy receives FDA orphan drug designation

Pharmalink AB, a privately held Swedish pharmaceutical company, has received orphan drug designation by the US Food and Drug Administration (FDA) for its product candidate Nefecon (PL-56) for patients with IgA nephropathy, also referred to as Berger's Disease. This program is presently in clinical development phase II.

13 Oct 2010

Study examines health-care costs among heart failure patients in Canada

As the population ages, health care epidemiologist Padma Kaul and cardiologist Paul Armstrong, researchers in the Faculty of Medicine & Dentistry at the University of Alberta, want health-care professionals to talk to their patients about their options on places to die, whether it be at home, in hospital or a palliative care facility like hospice.

13 Oct 2010

Buprenorphine implant decreases opioid usage in persons with opioid dependence

Helping to address the issue of medication adherence, persons with opioid dependence who had the medication buprenorphine implanted had less opioid use over 16 weeks, according to a study in the October 13 issue of JAMA.

13 Oct 2010

Patients with advanced cancer undergo common non-beneficial cancer screening tests

A sizeable proportion of patients with advanced cancer and a life expectancy of only a few years continue to undergo common cancer screening tests that are unlikely to provide meaningful benefit, according to a study in the October 13 issue of JAMA.

13 Oct 2010

Study examines restrictive strategy of RBC transfusion in patients undergoing elective cardiac surgery

Use of stricter guidelines for the use of red blood cell transfusions for patients undergoing cardiac surgery was associated similar rates of death and severe illness compared to patients who received more transfusions, according to a study in the October 13 issue of JAMA. Another study in this issue of JAMA examines the variation in the use of blood transfusions for patients undergoing cardiac surgery.

13 Oct 2010

PAXX100 audio device improves quality of life of people with tinnitus

Tinnitus Laboratory today announced the results of a clinical study that shows significant improvements from the use of PAXX100, a customized audio device for tinnitus management designed for long-term reduction of tinnitus perception.

13 Oct 2010

Pycnogenol effective in relieving tinnitus symptoms: Study

More than 50 million Americans will experience some degree of tinnitus in their lifetime, according to the American Tinnitus Association. Tinnitus is a hearing condition that causes the constant misperception of sound, including hissing, ringing and rushing noises. A study recently published in Panminerva Medica reveals that Pycnogenol (pic-noj-en-all), an antioxidant plant extract derived from the bark of the French maritime pine tree, is effective in relieving tinnitus symptoms by improving blood flow in the inner ear.

13 Oct 2010

Beta-Pro expands operations to meet increasing demand in $2 billion hepatocyte market

Beta-Pro LLC, announced today that it has expanded its operations to accommodate increasing demands from pharmaceutical drug discovery and research institutes in the $2 billion hepatocyte market. The human cellular sciences company now manages extensive laboratory facilities in the University of Virginia Research Park in Charlottesville, Virginia.

13 Oct 2010

Study compares minimally invasive and open surgeries for lower back pain

Rush University Medical Center is assessing whether minimally invasive surgery to relieve lower back pain differs from open surgery in terms of complication rate, recovery time, outcome and cost.

13 Oct 2010

USPTO grants HemoShear patent for human cell-based surrogate systems

HemoShear LLC, a biotechnology research company and leading developer of human cell-based surrogate systems for discovery and assessment of new drug compounds, today announced that the U.S. Patent and Trademark Office (USPTO) has granted it patent no. 7,811,782 entitled "Use of An In Vitro Hemodynamic Endothelial/Smooth Muscle Cell Co-Culture Model to Identify New Therapeutic Targets for Vascular Disease."

13 Oct 2010

New, longer lasting LVAD implanted in Canadian heart-failure patient

In a Canadian first, the Peter Munk Cardiac Centre used a new kind of left ventricular assist device (LVAD) to treat a patient with advanced heart failure. The new device is longer lasting than older generation LVADs and may eliminate the need for a second LVAD - a major drawback with the old technology.

13 Oct 2010

Gene Biodesign joins Roche NimbleGen Certified Service Provider Program

Roche NimbleGen announced today that Taipei-based genomic services provider Gene Biodesign Enterprises Co. has officially joined the Roche NimbleGen Certified Service Provider (CSP) Program.

13 Oct 2010

Study confirms increase in liability costs for hospitals and physicians

Hospitals and physicians should prepare for increasing liability costs, according to the 2010 Hospital Professional Liability and Physician Liability Benchmark Analysis created by Aon Risk Solutions, the global risk management business of Aon Corporation, in conjunction with the American Society for Healthcare Risk Management.

13 Oct 2010

Study demonstrates chitosan/IL-12 is an effective anti-tumor immunotherapy

A new study by a University of Arkansas biomedical engineer and his colleagues at the National Cancer Institute demonstrates further promise for chitosan/interleukin-12 as an effective anti-tumor immunotherapy.

13 Oct 2010

Patients with memory impairment have intact ability to hold information in mind: Research

Researchers at the University of California, San Diego School of Medicine, led by Larry R. Squire, PhD, professor of psychiatry, psychology and neurosciences at UC San Diego and a scientist at the VA San Diego Healthcare System, report that working memory of relational information where an object is located, for example remains intact even if key brain structures like the hippocampus are damaged.

13 Oct 2010

The Partnership at Drugfree.org issues statement on FDA approval of VIVITROL for opioid dependence

The U.S. Food and Drug Administration's approval of Alkermes' opioid dependence medication (VIVITROL) for the prevention of relapse to opioid dependence following opioid detoxification is positive news for families of young adults and all those who are struggling to overcome opioid addiction. Addiction, a disease of the human brain, is a chronic illness while opioid dependence is frequently characterized by relapse.

13 Oct 2010

SNM and SPR approve new North American Guidelines for Radiopharmaceutical Doses for Children

The Society of Nuclear Medicine (SNM) and the Society for Pediatric Radiology's Board of Directors recently approved new North American Guidelines for Radiopharmaceutical Doses for Children. These societies have expanded their pediatric radiation protection initiative by standardizing doses (based on body weight) for 11 nuclear medicine procedures commonly performed in children. The Alliance for Radiation Safety in Pediatric Imaging has collaborated in this effort, and will support efforts to promote the new, lower radiopharmaceutical doses.

13 Oct 2010

Prosensa receives £7.5M milestone payment in GSK2402968 Phase IIa trial for DMD

Prosensa, the Dutch biopharmaceutical company focusing on RNA modulating therapeutics, has announced that it received a £7.5m milestone payment from GlaxoSmithKline (GSK) as a result of achieving a data milestone in its Phase IIa open label extension trial of GSK2402968 (PRO051), being developed to treat Duchenne Muscular Dystrophy (DMD) under its agreement with GSK. The milestone payment was based upon achievement of a successful safety review, with no serious safety signals observed.

13 Oct 2010

Medical News

Hospitalizations and associated costs with peripheral artery disease increase as condition progresses

$1.5 million DOD award allows U-M scientists to pursue new application for nanoemulsion technology

Pharmalink's Nefecon for IgA nephropathy receives FDA orphan drug designation

Study examines health-care costs among heart failure patients in Canada

Buprenorphine implant decreases opioid usage in persons with opioid dependence

Patients with advanced cancer undergo common non-beneficial cancer screening tests

Study examines restrictive strategy of RBC transfusion in patients undergoing elective cardiac surgery

PAXX100 audio device improves quality of life of people with tinnitus

Pycnogenol effective in relieving tinnitus symptoms: Study

Beta-Pro expands operations to meet increasing demand in $2 billion hepatocyte market

Study compares minimally invasive and open surgeries for lower back pain

USPTO grants HemoShear patent for human cell-based surrogate systems

New, longer lasting LVAD implanted in Canadian heart-failure patient

Gene Biodesign joins Roche NimbleGen Certified Service Provider Program

Study confirms increase in liability costs for hospitals and physicians

Study demonstrates chitosan/IL-12 is an effective anti-tumor immunotherapy

Patients with memory impairment have intact ability to hold information in mind: Research

The Partnership at Drugfree.org issues statement on FDA approval of VIVITROL for opioid dependence

SNM and SPR approve new North American Guidelines for Radiopharmaceutical Doses for Children

Prosensa receives £7.5M milestone payment in GSK2402968 Phase IIa trial for DMD

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News